文献速递临床试验与 GCP

药用大麻(MedCan 3):评估THC/CBD(1:20)缓解癌症患者症状负担的随机、多中心、双盲、安慰剂对照试验——一项随机对照试验的研究方案

Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2024-05-01

晚期癌症患者常出现令人痛苦的症状,药用大麻素常被处方用于多种症状,但姑息治疗中大多数适应症缺乏证据支持。本研究为在澳大利亚昆士兰州多个中心开展的实用型、多中心、随机、安慰剂对照、双臂试验,计划招募150名接受姑息治疗的晚期癌症患者,通过远程试验模式招募非大都市地区患者,比较口服1:20 THC/CBD制剂(10 mg THC:200 mg CBD/mL)剂量递增(每日2.5 mg THC/50 mg CBD至30 mg THC/600 mg CBD)与安慰剂的疗效和安全性。主要目的是评估递增剂量的1:20 THC/CBD制剂与安慰剂相比对总症状困扰评分变化的影响。

要点

  • 本研究评估口服1:20 THC/CBD制剂剂量递增对晚期癌症姑息治疗患者总症状困扰评分的影响。
  • 计划招募150名参与者,采用远程试验模式以促进非大都市地区患者招募。
  • 设有2周患者自定滴定阶段和随后2周最终剂量评估阶段。

核心结论

  • MedCan-3是一项高质量、有足够把握度的安慰剂对照试验,将有助于证明THC:CBD 1:20口服药用大麻产品在减少该人群总症状困扰方面的效用。
  • 次要结局可能产生关于药用大麻在特定症状或特定癌症中作用的新假设。
  • 睡眠子研究将测试在该队列中使用体动记录仪和失眠严重程度指数(ISI)的可行性。
  • 这将是澳大利亚首个利用远程试验模式的大规模姑息治疗随机临床试验,若成功将对澳大利亚及国际上农村和偏远患者的试验可及性产生重大影响。

研究设计与样本

  • 实用型、多中心、随机、安慰剂对照、双臂试验,在澳大利亚昆士兰州多个中心招募150名参与者。
  • 采用远程试验模式促进非大都市地区患者招募。
  • 比较口服1:20 THC/CBD药用大麻素制剂(10 mg THC:200 mg CBD/mL)剂量递增与安慰剂的疗效和安全性结局。
  • 滴定剂量范围为每日2.5 mg THC/50 mg CBD至30 mg THC/600 mg CBD。
  • 设2周患者自定滴定阶段以达到症状缓解或不可耐受副作用的剂量,随后2周在最终剂量下评估。

主要发现

  • 主要目的是评估递增剂量的1:20 THC/CBD药用大麻素制剂与安慰剂相比对总症状困扰评分变化的影响。
  • 次要目的包括确定患者自定的有效剂量、对睡眠质量和整体生活质量的影响。
  • 部分患者将加入子研究,更严格地评估对睡眠的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Distressing symptoms are common in advanced cancer. Medicinal cannabinoids are commonly prescribed for a variety of symptoms. There is little evidence to support their use for most indications in palliative care. This study aims to assess a 1:20 delta-9-tetrahydrocannabinol/cannabidiol (THC/CBD) cannabinoid preparation in the management of symptom distress in patients with advanced cancer undergoing palliative care. METHODS AND DESIGN: One hundred and fifty participants will be recruited across multiple sites in Queensland, Australia. A teletrial model will facilitate the recruitment of patients outside of major metropolitan areas. The study is a pragmatic, multicenter, randomised, placebo-controlled, two-arm trial of escalating doses of an oral 1:20 THC/CBD medicinal cannabinoid preparation (10 mg THC:200 mg CBD/mL). It will compare the efficacy and safety outcomes of a titrated dose range of 2.5 mg THC/50mgCBD to 30 mg THC/600 mg CBD per day against a placebo. There is a 2-week patient-determined titration phase, to reach a dose that achieves symptom relief or intolerable side effects, with a further 2 weeks of assessment on the final dose. The primary objective is to assess the effect of escalating doses of a 1:20 THC/CBD medicinal cannabinoid preparation against placebo on change in total symptom distress score, with secondary objectives including establishing a patient-determined effective dose, the effect on sleep quality and overall quality of life. Some patients will be enrolled in a sub-study which will more rigorously evaluate the effect on sleep. DISCUSSION: MedCan-3 is a high-quality, adequately powered, placebo-controlled trial which will help demonstrate the utility of a THC:CBD 1:20 oral medicinal cannabis product in reducing total symptom distress in this population. Secondary outcomes may lead to new hypotheses regarding medicinal cannabis' role in particular symptoms or in particular cancers. The sleep sub-study will test the feasibility of using actigraphy and the Insomnia Severity Index (ISI) in this cohort. This will be the first large-scale palliative care randomised clinical trial to utilise the teletrial model in Australia. If successful, this will have significant implications for trial access for rural and remote patients in Australia and internationally. TRIAL REGISTRATION: ANZCTR ACTRN12622000083796 . Protocol number 001/20. Registered on 21 January 2022. Recruitment started on 8 August 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gurgenci T, Hardy J, Huggett G, et al. Medicinal Cannabis (MedCan 3): a randomised, multicentre, double-blind, placebo-controlled trial to assess THC/CBD (1:20) to relieve symptom burden in patients with cancer-a study protocol for a randomised controlled trial. Trials. 2024. PMID: 38693590. doi:10.1186/s13063-024-08091-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。